Abstract 582P
Background
Leptomeningeal metastases (LM) is one of the most severe complications of NSCLC and always accompanied with poor prognosis. Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with high brain penetration and wide therapeutic window. This study aims to evaluate the efficacy and safety of furmonertinib at 240mg/day in EGFR mutated NSCLC patients with leptomeningeal metastases (LM).
Methods
Patients were diagnosed as LM according to EANO-ESMO criteria. The primary endpoint was overall survival (OS), time to treatment discontinuation (TTD) and clinical response rate were secondary endpoints. Clinical response rate assessed with improvement of neurologic symptoms or signs and changes in the performance status. LM were assessed by investigator according to RANO-LM radiologic criteria.
Results
Between May 2021 and August 2023, 31 patients at Henan Cancer Hospital were enrolled. 26 (83.9%) patients received EGFR-TKI therapy prior to receive furmonertinib, 19 (61.3%) patients received at least 2 lines treatment, 21 (67.7%) patients received other 3rd generation EGFR-TKI therapy. The median age was 58 years (range:36-75), 23 (74.2%) were females. 21 (67.7%) patients with ECOG 3. 23 OS events had occurred at the data cut-off (1 August 2023), Median OS was 8.433 months (95%CI, 5.623 to 11.243) with 74.2% maturity. Median TTD was 7.633 months (95%CI, 3.688 to 11.579). The clinical response rate was 77.4%. The LM ORR and DCR assessed by investigator according to RANO-LM radiologic criteria were 54.2% and 95.8%, respectively. The safety profiles were consistent with previous reports for furmonertinib.
Conclusions
Furmonertinib 240mg/day has demonstrated clinically significant efficacy as first line and salvage therapy in patients with EGFR-mutant NSCLC and leptomeningeal metastases.
Clinical trial identification
ChiCTR2300072092.
Editorial acknowledgement
Legal entity responsible for the study
Qiming Wang.
Funding
Henan Province Health and Youth Subject Leader Training Project (No. [2020]60) The Excellent Young Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (No. YXKC2020046). Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer (No. [2021]10).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract